SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

13 Nov 2025 Evaluate
The September 2025 quarter revenue stood at Rs. 6423.40 millions, up 9.13% as compared to Rs. 5885.90 millions during the corresponding quarter last year.A slim rise of 19.37% was recorded in the Net profit for the quarter ended September 2025 to Rs. 1890.20  millions  From Rs. 1583.50 millions.Operating Profit saw a handsome growth to 2717.80 millions from 2323.20 millions in the quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 6423.40 5885.90 9.13 12453.90 11514.50 8.16 22813.50 21931.70 4.02
Other Income 418.50 430.70 -2.83 1090.20 849.10 28.39 1722.50 1805.10 -4.58
PBIDT 2717.80 2323.20 16.99 5489.70 4516.50 21.55 9124.80 8158.10 11.85
Interest 21.30 21.00 1.43 53.80 42.10 27.79 84.10 154.10 -45.43
PBDT 2696.50 2302.20 17.13 5435.90 4474.40 21.49 10768.80 8083.50 33.22
Depreciation 142.80 149.90 -4.74 286.90 295.90 -3.04 607.90 622.80 -2.39
PBT 2553.70 2152.30 18.65 5149.00 4178.50 23.23 10160.90 7460.70 36.19
TAX 663.50 568.80 16.65 1341.30 1087.90 23.29 2484.90 1947.40 27.60
Deferred Tax 8.60 -30.10 -128.57 12.50 -61.50 -120.33 -156.10 361.10 -143.23
PAT 1890.20 1583.50 19.37 3807.70 3090.60 23.20 7676.00 5513.30 39.23
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 42.31 39.47 7.20 44.08 39.22 12.38 40.00 37.20 7.53

Pfizer Share Price

4891.60 -62.45 (-1.26%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×